Segment and Geographic Information (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended																12 Months Ended
	Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 29, 2013		Mar. 30, 2013		Dec. 29, 2012		Sep. 29, 2012		Jun. 28, 2014 number		Jun. 29, 2013		Jun. 30, 2012
Segment Reporting Information [Line Items]
Number of Reportable Segments																	5
Write-off of in-process research and development					$ 6.0												$ 6.0		$ 9.0		$ 0
Restructuring charges	10.5		19.5		14.9												47.0		2.9		8.8
Net sales	1,144.2	[1]	1,004.2	[2]	979.0	[3]	933.4	[4]	967.2	[5]	919.8	[6]	883.0	[7]	769.8	[8]	4,060.8		3,539.8		3,173.2
Operating income																	567.0		679.1		569.2
Operating income %																	14.00%		19.20%		17.90%
Total assets	13,880.2								5,350.8								13,880.2		5,350.8		4,024.0
Capital expenditures																	171.6		132.2		120.2
Property and equip, net	779.9								681.4								779.9		681.4		578.4
Depreciation/amortization																	358.9		160.2		135.3
Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Net sales																	2,219.0		2,089.0		1,815.8
Operating income																	368.6		363.2		315.3
Operating income %																	16.60%		17.40%		17.40%
Total assets	3,774.5								2,409.0								3,774.5		2,409.0		1,651.4
Capital expenditures																	115.9		85.5		76.3
Property and equip, net	475.7								404.1								475.7		404.1		328.0
Depreciation/amortization																	63.8		53.8		41.0
Consumer Healthcare [Member] | Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales																	504.0	[9]	536.0	[9]	452.3	[9]
Consumer Healthcare [Member] | Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales																	510.1	[9]	500.6	[9]	447.2	[9]
Consumer Healthcare [Member] | Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales																	400.1	[9]	388.8	[9]	402.4	[9]
Consumer Healthcare [Member] | Smoking Cessation [Member]
Segment Reporting Information [Line Items]
Net sales																	236.8		193.2		170.6
Consumer Healthcare [Member] | Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales																	178.0		123.2		0
Consumer Healthcare [Member] | Other CHC [Member]
Segment Reporting Information [Line Items]
Net sales																	390.0	[10],[9]	347.3	[10],[9]	343.3	[10],[9]
Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																	551.7		508.4		501.0
Operating income																	40.5		35.2		25.4
Operating income %																	7.30%		6.90%		5.10%
Total assets	1,077.2								949.7								1,077.2		949.7		951.0
Capital expenditures																	7.3		7.8		14.4
Property and equip, net	88.6								92.8								88.6		92.8		94.5
Depreciation/amortization																	38.5		38.3		39.0
Nutritionals [Member] | Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales																	374.8		350.1		352.7
Nutritionals [Member] | Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales																	176.9		158.3		148.3
Generic prescription drugs [Member]
Segment Reporting Information [Line Items]
Net sales																	927.1		709.5		617.4
Operating income																	349.8		263.2		213.5
Operating income %																	37.70%		37.10%		34.60%
Total assets	2,537.2								1,604.9								2,537.2		1,604.9		1,072.6
Capital expenditures																	32.9		17.7		8.0
Property and equip, net	104.8								80.8								104.8		80.8		67.6
Depreciation/amortization																	86.5		54.9		42.2
Active pharmaceutical ingredients [Member]
Segment Reporting Information [Line Items]
Net sales																	137.6		159.3		165.8
API [Member]
Segment Reporting Information [Line Items]
Net sales																	137.6		159.3		165.8
Operating income																	46.1		48.9		53.9
Operating income %																	33.50%		30.70%		32.50%
Total assets	288.0								284.5								288.0		284.5		258.4
Capital expenditures																	10.4		17.3		18.5
Property and equip, net	95.7								92.7								95.7		92.7		79.6
Depreciation/amortization																	11.4		9.1		9.3
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales																	146.7		0		0
Operating income																	(68.6)
Operating income %																	(46.70%)
Total assets	6,096.6																6,096.6
Capital expenditures																	0
Property and equip, net	2.1																2.1
Depreciation/amortization																	154.4
Pharaceutical and medical diagnostic products [Member]
Segment Reporting Information [Line Items]
Net sales																	78.7		73.6		73.3
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales																	78.7		73.6		73.3
Operating income																	4.0		3.4		2.0
Operating income %																	5.20%		4.60%		2.70%
Total assets	106.7								102.7								106.7		102.7		90.7
Capital expenditures																	5.1		3.8		3.0
Property and equip, net	13.0								11.1								13.0		11.1		8.7
Depreciation/amortization																	4.3		4.0		3.8
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales																	0		0		0
Operating income																	(173.4)		(34.7)		(40.9)
Operating income %																	0.00%		0.00%		0.00%
Total assets	0								0								0		0		0
Capital expenditures																	0		0		0
Property and equip, net	0								0								0		0		0
Depreciation/amortization																	0		0		0
Net Sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Number of major customers																	1		1		1
Concentration risk percentage																	19.00%		19.00%		20.00%
IRELAND [Member]
Segment Reporting Information [Line Items]
Net sales																	146.7		0		0
Property and equip, net	2.0								0								2.0		0
UNITED STATES
Segment Reporting Information [Line Items]
Net sales																	3,291.6		2,978.1		2,693.6
Property and equip, net	530.7								468.4								530.7		468.4
ISRAEL [Member]
Segment Reporting Information [Line Items]
Property and equip, net	119.6								98.0								119.6		98.0
Outside United States [Member]
Segment Reporting Information [Line Items]
Net sales																	622.5		561.7		479.6
Property and equip, net	$ 127.6								$ 115.0								$ 127.6		$ 115.0

[1] Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

[2] Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.

[3] Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D of $6.0 million related to Paddock and Rosemont.

[4] Includes Elan transaction costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.

[5] Includes a pre-tax charge to cost of sales of $1.2 million associated with the step-up in value of inventory related to the Rosemont acquisition, $5.6 million of restructuring and other integration-related costs associated with the Velcera acquisition and a $9.0 million impairment charge related to the write-off of IPR&D.

[6] Includes a pre-tax charge to cost of sales of $1.9 million associated with the step-up in value of inventory related to the Rosemont acquisition, approximately $3.1 million of acquisition costs associated with the Rosemont and Velcera acquisitions and a $1.6 million loss related to the sale of the Company's investment securities.

[7] Includes a pre-tax charge to cost of sales of $7.7 million associated with the step-up in value of inventory related to the Sergeant's acquisition, $1.5 million of severance costs associated with the Cobrek acquisition and a $3.0 million loss on the sale of investment related to Cobrek.

[8] Includes a pre-tax charge of approximately $1.9 million of acquisition costs associated with the Sergeant's acquisition.

[9] ncludes sales from the Company's contract manufacturing business.

[10] Consists primarily of feminine hygiene, diabetes care, dermatological care and other miscellaneous or otherwise uncategorized product lines and markets.